TY - JOUR T1 - Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. JO - Pharmacoeconomics PY - 2003/01/01 AU - Walters SJ AU - Whitfield M AU - Akehurst RL AU - Chilcott JB ED - DO - DOI: 10.2165/00019053-200321020-00005 VL - 21 IS - 2 SP - 129 EP - 138 Y2 - 2025/01/13 ER -